Neuropsychiatric side effects of FK506 vs. cyclosporine A. First-week postoperative findings.
The authors studied 31 liver transplant patients to compare neuropsychiatric side effects of a newer immunosuppressant, FK506, to cyclosporine A (CYA). Patients were randomly assigned to either FK506 or CYA. At the 1-week postoperative stage, cognitive status was assessed with the Mini-Mental State Exam, Trailmaking Tests (TMT) A and B, Delirium Rating Scale, and a neuropsychiatric symptom checklist. No statistically significant differences were found on any outcome variable between these two drugs, though scores on the TMTs were impaired as compared with published norms. The FK506 patients had moderately impaired TMT scores, whereas the CYA patients had only mild impairment. The patients demonstrate good cognitive recovery at 1 week post-transplantation, with only mild evidence of cognitive impairment.
DiMartini
A F
AF
Department of Psychiatry, Western Psychiatric Institute & Clinics, Pittsburgh, PA 15213, USA.
Trzepacz
P T
PT
Pajer
K A
KA
Faett
D
D
Fung
J
J
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects*; D003693:Delirium / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D008875:Middle Aged; D011446:Prospective Studies; D016559:Tacrolimus / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus